Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …

As acute myeloid leukemia (AML) xenograft models improve, the potential for using them to
evaluate novel therapeutic strategies becomes more appealing. Currently, there is little …

Introduction: Pediatric relapsed acute myeloid leukemia (AML) remains lethal in the majority
of cases, despite intensive therapy. Randomized trials are largely lacking, and the main …

Expression of apoptosis-regulating proteins (B-cell CLL/lymphoma 2-BCL-2, Myeloid Cell
Leukemia 1-MCL-1, BCL-2 like 1-BCL-X and BCL-2-associated X protein-BAX) in acute …

The prognostic significance of early response to treatment has not been reported in relapsed
pediatric acute myeloid leukemia. In order to identify an early and easily applicable …

Proteasome inhibition has been recognized as a novel treatment modality in hematologic
malignancies. Initially, the reversible proteasome inhibitor bortezomib demonstrated efficacy …

Targeted inhibition of members of the TAM (TYRO-3, AXL, MERTK) family of receptor
tyrosine kinases has recently been investigated as a novel strategy for treatment of …

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy
protocols, underscoring the unmet need for new treatment options, such as proteasome …

Novel treatment strategies are of paramount importance to improve clinical outcomes in
pediatric AML. Since chemotherapy is likely to remain the cornerstone of curative treatment …